• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术后放疗在食管鳞癌中对微小切缘侵犯的作用。

Role of postoperative radiotherapy for microscopic margin involvement in the squamous cell carcinoma of esophagus.

机构信息

Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.

出版信息

Cancer Res Treat. 2013 Sep;45(3):202-9. doi: 10.4143/crt.2013.45.3.202. Epub 2013 Sep 30.

DOI:10.4143/crt.2013.45.3.202
PMID:24155679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3804732/
Abstract

PURPOSE

The objective of this study was to assess the effect of postoperative radiotherapy on the outcome of esophageal cancer with microscopically positive resection margin by comparing the results with those of patients with negative resection margin.

MATERIALS AND METHODS

Medical records of 88 patients treated with macroscopic resection followed by postoperative radiotherapy for stage II or III squamous cell carcinoma of the esophagus from June 1984 to March 2008 were reviewed. Twelve patients had received chemotherapy. Patients were classified into two groups based on resection margin status: negative resection margin (group A, n=66) and microscopically positive resection margin (group B, n=22). Median follow-up duration of living patients was 68 months (range, 18 to 115 months). Median total radiation dose of group A and group B was 51.5 Gy (range, 45 to 69 Gy) and 52.1 Gy (range, 45 to 64 Gy), respectively.

RESULTS

Median overall survival and disease-free survival were 15 and 10 months, respectively. The five-year overall survival, disease-free survival, and local control rates for group A and group B were 15.9% and 16.4%, 13.5% and 9.1%, and 76.3% and 69.6%, respectively. No statistically significant difference in terms of overall survival, disease-free survival, and local control (p=0.295, p=0.209, and p=0.731, respectively) was observed between group A and group B. Seven patients experienced toxicity of grade 3 or higher.

CONCLUSION

A significant portion of patients with margin involvement reached long term survival after addition of postoperative radiotherapy. These results suggest a potential role of postoperative radiotherapy, especially for patients with margin involvement.

摘要

目的

本研究旨在通过比较阳性切缘和阴性切缘患者的结果,评估术后放疗对显微镜下阳性食管切除边缘的食管癌患者预后的影响。

材料与方法

回顾分析 1984 年 6 月至 2008 年 3 月间接受根治性切除术后行术后放疗的 88 例 II 期或 III 期食管鳞癌患者的病历资料。其中 12 例患者接受了化疗。根据切缘状态将患者分为两组:阴性切缘组(A 组,n=66)和显微镜下阳性切缘组(B 组,n=22)。有生存记录的患者中位随访时间为 68 个月(18-115 个月)。A 组和 B 组的中位总放疗剂量分别为 51.5 Gy(45-69 Gy)和 52.1 Gy(45-64 Gy)。

结果

中位总生存期和无病生存期分别为 15 个月和 10 个月。A 组和 B 组的 5 年总生存率、无病生存率和局部控制率分别为 15.9%和 16.4%、13.5%和 9.1%、76.3%和 69.6%。A 组和 B 组在总生存率、无病生存率和局部控制率方面无统计学差异(p=0.295,p=0.209,p=0.731)。7 例患者发生 3 级及以上毒性。

结论

术后放疗可使部分切缘受累的患者获得长期生存。这些结果提示术后放疗可能具有一定作用,特别是对切缘受累的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/a85ba96e067f/crt-45-202-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/f57ba9d3ccb4/crt-45-202-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/76d769d92e1e/crt-45-202-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/af5afada4ce7/crt-45-202-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/ecaf0048df05/crt-45-202-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/a85ba96e067f/crt-45-202-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/f57ba9d3ccb4/crt-45-202-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/76d769d92e1e/crt-45-202-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/af5afada4ce7/crt-45-202-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/ecaf0048df05/crt-45-202-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cce0/3804732/a85ba96e067f/crt-45-202-g005.jpg

相似文献

1
Role of postoperative radiotherapy for microscopic margin involvement in the squamous cell carcinoma of esophagus.术后放疗在食管鳞癌中对微小切缘侵犯的作用。
Cancer Res Treat. 2013 Sep;45(3):202-9. doi: 10.4143/crt.2013.45.3.202. Epub 2013 Sep 30.
2
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.术前超分割放化疗用于既往盆腔放疗后的局部复发性直肠癌患者:一项多中心II期研究。
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18.
3
Positive impact of radiation dose on disease free survival and locoregional control in postoperative radiotherapy for squamous cell carcinoma of esophagus.放射剂量对食管鳞状细胞癌术后放疗无病生存期和局部区域控制的积极影响。
Dis Esophagus. 2009;22(4):298-304. doi: 10.1111/j.1442-2050.2008.00882.x. Epub 2008 Nov 10.
4
High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma.大剂量放疗联合化疗后挽救性食管切除术治疗局部晚期食管鳞癌。
Thorac Cancer. 2017 May;8(3):219-228. doi: 10.1111/1759-7714.12427. Epub 2017 Mar 21.
5
Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications.上颌窦鳞状细胞癌的术后放疗:局部控制及晚期并发症分析
Oncol Rep. 2001 Mar-Apr;8(2):315-9. doi: 10.3892/or.8.2.315.
6
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.诱导化疗改善了接受放化疗后手术的可切除食管癌患者的预后。
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36. doi: 10.1016/j.ijrobp.2004.03.033.
7
Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study.III期胸腺瘤:手术及术后放疗后的失败模式及其对未来研究的启示
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):927-33. doi: 10.1016/s0360-3016(99)00514-3.
8
Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.局部晚期直肠癌术前超分割放化疗的I期剂量递增试验。
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):43-50. doi: 10.1016/s0360-3016(98)00172-2.
9
Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy.肝外胆管癌:单纯手术与手术后放疗的比较。
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):194-8. doi: 10.1016/j.ijrobp.2009.07.003. Epub 2009 Nov 10.
10
Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.新辅助同步放化疗后行根治性高剂量放疗或手术治疗可切除的胸段食管癌。
Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1049-59. doi: 10.1016/s0360-3016(97)00900-0.

引用本文的文献

1
Adjuvant radiotherapy in oesophageal cancer with positive circumferential resection margins-recurrence and survival outcomes.食管癌环周切缘阳性患者的辅助放疗——复发及生存结果
J Gastrointest Oncol. 2019 Jun;10(3):483-491. doi: 10.21037/jgo.2019.01.26.
2
Post-operative radiotherapy is associated with improved survival in esophageal cancer with positive surgical margins.术后放疗与手术切缘阳性的食管癌患者生存率提高相关。
J Gastrointest Oncol. 2017 Dec;8(6):953-961. doi: 10.21037/jgo.2017.08.12.
3
Positive esophageal proximal resection margin: an important prognostic factor for esophageal cancer that warrants adjuvant therapy.

本文引用的文献

1
Radiation therapy in the postoperative management of esophageal cancer.食管癌术后的放射治疗。
J Gastrointest Oncol. 2010 Dec;1(2):102-11. doi: 10.3978/j.issn.2078-6891.2010.013.
2
Preoperative chemoradiotherapy for esophageal or junctional cancer.术前放化疗治疗食管或食管胃交界癌。
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
3
International survey on esophageal cancer: part II staging and neoadjuvant therapy.国际食管癌调查:第二部分 分期与新辅助治疗
食管近端切缘阳性:食管癌的一个重要预后因素,需要辅助治疗。
J Thorac Dis. 2016 Sep;8(9):2512-2518. doi: 10.21037/jtd.2016.08.61.
Dis Esophagus. 2009;22(3):203-10. doi: 10.1111/j.1442-2050.2008.00930.x. Epub 2009 Jan 23.
4
Positive impact of radiation dose on disease free survival and locoregional control in postoperative radiotherapy for squamous cell carcinoma of esophagus.放射剂量对食管鳞状细胞癌术后放疗无病生存期和局部区域控制的积极影响。
Dis Esophagus. 2009;22(4):298-304. doi: 10.1111/j.1442-2050.2008.00882.x. Epub 2008 Nov 10.
5
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.放射治疗肿瘤学组(RTOG)8911试验(美国肿瘤协作组113)的长期结果:一项随机分组试验,比较食管癌化疗后手术与单纯手术的疗效。
J Clin Oncol. 2007 Aug 20;25(24):3719-25. doi: 10.1200/JCO.2006.10.4760.
6
Lymphadenectomy extent is closely related to long-term survival in esophageal cancer.淋巴结清扫范围与食管癌的长期生存密切相关。
Eur J Cardiothorac Surg. 2007 Feb;31(2):154-60. doi: 10.1016/j.ejcts.2006.10.033. Epub 2006 Dec 4.
7
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.单纯手术与放化疗后手术治疗可切除食管癌的对比:一项随机对照III期试验
Lancet Oncol. 2005 Sep;6(9):659-68. doi: 10.1016/S1470-2045(05)70288-6.
8
Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience.术后放化疗作为切除的胃食管腺癌辅助治疗的审计:澳大利亚多中心经验
ANZ J Surg. 2004 Nov;74(11):951-6. doi: 10.1111/j.1445-1433.2004.03218.x.
9
Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival.1975 - 2001年美国癌症现状年度报告,附生存情况专题内容
Cancer. 2004 Jul 1;101(1):3-27. doi: 10.1002/cncr.20288.
10
Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit.食管癌的切缘受累情况与预后:专科单位的10年经验
Eur J Surg Oncol. 2004 Apr;30(3):313-7. doi: 10.1016/j.ejso.2003.11.009.